HER-2/Neu Status in Gastric Carcinomas in a Series of Egyptian Patients and Its Relation to Ki-67 Expression


Objective: HER-2/neu status in gastric carcinomas (GCs) has not been studied before in the Egyptian population. Materials and Methods: Seventy-three GCs were evaluated for the expression of HER-2/neu and Ki-67 using immunohistochemistry (IHC). Fluorescence in situ Hybridization (FISH) was done for HER2/neu IHC score 2+ cases. Results: Out of the 73 gastric carcinomas, 23 (31.5%) were score 0, 17 (23.3%) were score 1+, 23 (31.5%) were score 2+, and 10 (13.7%) were score 3+. FISH analysis revealed that the HER-2/neu gene was amplified in 11 out of the 23 cases (47.8%) scored 2+ by IHC. Therefore, the overall HER-2/neu positivity rate was 28.8% and it was significantly associated with higher T-stage and lymphovascular invasion (LVI). The Ki-67 expression rate ranged between 10% and 100%, with 84.9% of the cases (n = 62) featuring high Ki-67 scores. High Ki-67 score was significantly associated with male sex, tumor grade, and number of positive nodes. HER-2/neu protein expression correlated significantly with Ki-67 score. Twenty tumors showed combined HER-2/neu positivity and high Ki-67 score and were significantly associated with higher T-stage and occurrence of LVI, implying a more aggressive behavior. Conclusions: The rate of HER-2/neu positive GCs in our series simulates universal rates, thereby mandating routine evaluation of HER-2/neu status in all GCs submitted to our laboratory to benefit from trastuzumab therapy. Further studies on a larger number of GCs are required to prove that the concurrent HER-2/neu positivity and high Ki-67 score are markers of worse prognosis.

Share and Cite:

El-Gendi, S. , Talaat, I. and Abdel-Hadi, M. (2015) HER-2/Neu Status in Gastric Carcinomas in a Series of Egyptian Patients and Its Relation to Ki-67 Expression. Open Journal of Pathology, 5, 101-113. doi: 10.4236/ojpathology.2015.54014.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Guggenheim, D.E. and Shah, M.A. (2013) Gastric Cancer Epidemiology and Risk Factors. Journal of Surgical Oncology, 107, 230-236. http://dx.doi.org/10.1002/jso.23262
[2] Alieldin, N. (2002-2010) NCI Hospital-Based Registry.
[3] Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., et al. (2013) GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. International Agency for Research on Cancer, Lyon. http://globocan.iarc.fr/Pages/references.aspx
[4] McGrath, SC., Ebert, M. and Röcken, C. (2007) Gastric Adenocarcinoma: Epidemiology, Pathology and Pathogenesis. Cancer Therapy, 5, 877-894.
[5] Yan, S.Y., Hu, Y., Fan, J.G., Tao, G.Q., Lu, Y.M., Cai, X., Yu, B.H. and Du, Y.Q. (2011) Clinicopathologic Significance of HER-2/Neu Protein Expression and Gene Amplification in Gastric Carcinoma. World Journal of Gastroenterology, 17, 1501-1506. http://dx.doi.org/10.3748/wjg.v17.i11.1501
[6] Ross, J.S., Slodkowska, E.A., Symmans, W.F., Pusztai, L., Ravdin, P.M. and Hortobagyi, G.N. (2009) The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. Oncologist, 14, 320-368. http://dx.doi.org/10.1634/theoncologist.2008-0230
[7] Ross, J.S. and McKenna, B.J. (2001) The HER-2/Neu Oncogene in Tumors of the Gastrointestinal Tract. Cancer Invest, 19, 554-568. http://dx.doi.org/10.1081/CNV-100103852
[8] Bang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., Aprile, G., Kulikov, E., Hill, J., Lehle, M., Rüschoff, J. and Kang, Y.K., ToGA Trial Investigators (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697.
[9] Amrani, H.J.,Marchoudi, N., Sadaoui,I., Mahfoud, W., Elgnaoui, N., Haddad, F., Fechtali, T. and Benomar, H. (2014) Ki-67 Expression in Gastric Cancer and Correlation with Clinico-Pathological Characteristics. International Journal of Scientific and Research Publications, 4, 1-4.
[10] Czyzewska, J., Guzińska-Ustymowicz, K., Pryczynicz, A., Kemona, A. and Bandurski, R. (2009) Immunohistochemical Evaluation of Ki-67, PCNA and MCM2 Proteins Proliferation Index (PI) in Advanced Gastric Cancer. Folia Histochemica Et Cytobiologica, 47, 289-296.
[11] Endl, E. and Gerdes, J. (2000) The Ki-67 Protein: Fascinating Forms and an Unknown Function. Experimental Cell Research, 257, 231-237. http://dx.doi.org/10.1006/excr.2000.4888
[12] Fred, T., Carneiro, B.F., Hruban, R.H. and Theise, N.D. (2010) WHO Classification of Tumours of the Digestive System. 4th Edition, IARC, Lyon, 417p.
[13] Washington, K. (2010) 7th Edition of the AJCC Cancer Staging Manual: Stomach. Annals of Surgical Oncology, 17, 3077-3079. http://dx.doi.org/10.1245/s10434-010-1362-z
[14] Hofmann, M., Stoss, O., Shi, D., Buttner, R., van de Vijver, M., Kim, W., Ochiai, A., Ruschoff, J. and Henkel, T. (2008) Assessment of a HER2 Scoring System for Gastric Cancer: Results from a Validation Study. Histopathology, 52, 797-805. http://dx.doi.org/10.1111/j.1365-2559.2008.03028.x
[15] Dowsett, M., Nielsen, T.O., A’Hern, R., Bartlett, J., Coombes, R.C., Cuzick, J., Ellis, M., Henry, N.L., Hugh, J.C., Lively, T., McShane, L., Paik, S., Penault-Llorca, F., Prudkin, L., Regan, M., Salter, J., Sotiriou, C., Smith, I.E., Viale, G., Zujewski, J.A. and Hayes, D.F. (2011) Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 103, 1656-1664.http://dx.doi.org/10.1093/jnci/djr393
[16] Zeeneldin, A.A., Ramadan, H., El Gammal, M.M., Saber, M.M., Elgamal, D. and Sherisher, M.A. (2014) Gastric Carcinoma at Tanta Cancer Center: A Comparative Retrospective Clinico-Pathological Study of the Elderly versus the Non-Elderly. Journal of the Egyptian National Cancer Institute, 26,127-137.
[17] Bang, Y., Chung, H., Xu, J., Lordick, F., Sawaki, A., Al-Sakaff, N., Lipatov, O., See, C., Rueschoff, J. and Van Cutsem, E. (2009) Pathological Features of Advanced Gastric Cancer (GC): Relationship to Human Epidermal Growth Factor Receptor 2 (HER2) Positivity in the Global Screening Program of the ToGA Trial. Journal of Clinical Oncology, 27, 15S.
[18] Lemoine, N.R., Jain, S., Silvestre, F., Lopes, C., Hughes, C.M., McLelland, E., Gullick, W.J. and Filipe, M.I. (1991) Amplification and Overexpression of the EGF Receptor and c-erbB-2 Proto-Oncogenes in Human Stomach Cancer. British Journal of Cancer, 64, 79-83. http://dx.doi.org/10.1038/bjc.1991.243
[19] Kameda, T., Yasui, W., Yoshida, K., Tsujino, T., Nakayama, H., Ito, M., Ito, H. and Tahara, E. (1990) Expression of ERBB2 in Human Gastric Carcinomas: Relationship between p185ERBB2 Expression and the Gene Amplification. Cancer Research, 50, 8002-8029.
[20] Hollywood, D.P. and Hurst, H.C. (1993) A Novel Transcription Factor, OB2-1, Is Required for Overexpression of the Proto-Oncogene c-erbB-2 in Mammary Tumour Lines. The EMBO Journal, 12, 2369-2375.
[21] Yano, T., Ochiai, A. and Doi, T. (2004) Expression of HER2 in Gastric Cancer: Comparison between Protein Expression and Gene Amplification Using a New Commercial Kit. Journal of Clinical Oncology, 22, 14S.
[22] Lordick, F., Bang, Y.J., Kang, Y.K., et al. (2007) HER2-Positive Advanced Gastric Cancer: Similar HER2-Positivity Levels to Breast Cancer. European Journal of Cancer, 5, 271.
[23] Kataoka, Y., Okabe, H., Yoshizawa, A., Minamiguchi, S., Yoshimura, K., Haga, H. and Sakai, Y. (2012) HER2 Expression and Its Clinicopathological Features in Resectable Gastric Cancer. Gastric Cancer, 16, 84-93.http://dx.doi.org/10.1007/s10120-012-0150-9
[24] Bozzetti, C., Negri, F.V., Lagrasta, C.A., Crafa, P., Bassano, C., Tamagnini, I., Gardini, G., Nizzoli, R., Leonardi, F., Gasparro, D., Camisa, R., Capelli, S., Silini, E.M. and Ardizzoni, A. (2011) Comparison of HER2 Status in Primary and Paired Metastatic Sites of Gastric Carcinoma. British Journal of Cancer, 104, 1372-1376.http://dx.doi.org/10.1038/bjc.2011.121
[25] Gravalos, C. and Jimeno, A. (2008) HER2 in Gastric Cancer: A New Prognostic Factor and a Novel Therapeutic Target. Annals of Oncology, 19, 1523-1529. http://dx.doi.org/10.1038/bjc.2011.121
[26] Zhang, X.L., Yang, Y.S., Xu, D.P., Qu, J.H., Guo, M.Z., Gong, Y. and Huang, J. (2009) Comparative Study on Overexpression of HER2/Neu and HER3 in Gastric Cancer. World Journal of Surgery, 33, 2112-2118.http://dx.doi.org/10.1007/s00268-009-0142-z
[27] Kim, K.C., Koh, Y.W., Chang, H.M., Kim, T.H., Yook, J.H., Kim, B.S., Jang, S.J. and Park, Y.S. (2011) Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1,414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays. Annals of Surgical Oncology, 18, 2833-2840.http://dx.doi.org/10.1245/s10434-011-1695-2
[28] Wu, H.M., Liu, Y.H., Lin, F., Xu, F.P., Luo, D.L., Zhang, F., Zhuang, H.G., Luo, X.L., Wu, W.L. and Lin, X.T. (2011) Association of HER2 Protein Expression with Clinicopathologic Features and Prognosis in Chinese Patients with Gastric Carcinoma. Chinese Journal of Pathology, 40, 296-299.
[29] Wu, H.W., Qin, C.Y., Huang, J.L., Kong, X.Y., Wang, W.J. and Bai, W.K. (2014) Correlations of β-Catenin, Ki67 and Her-2/Neu with Gastric Cancer. Asian Pacific Journal of Tropical Medicine, 7, 257-261.http://dx.doi.org/10.1016/S1995-7645(14)60033-X
[30] Xiao, L.J., Zhao, S., Zhao, E.H., Zheng, X., Gou, W.F., Takano, Y. and Zheng, H.C. (2013) Clinicopathological and Prognostic Significance of Ki-67, Caspase-3 and p53 Expression in Gastric Carcinomas. Oncology Letters, 6, 1277- 1284.
[31] Protzel, C., Knoedel, J., Zimmermann, U., Woenckhaus, C., Poetsch, M. and Giebel, J. (2007) Expression of Proliferation Marker Ki67 Correlates to Occurrence of Metastasis and Prognosis, Histological Subtypes and HPV DNA Detection in Penile Carcinomas. Histology and Histopathology, 22, 1197-1204.
[32] Yin, Y., Zeng, K., Wu, M., Ding, Y., Zhao, M. and Chen, Q. (2014) The Levels of Ki-67 Positive Are Positively Associated with Lymph Node Metastasis in Invasive Ductal Breast Cancer. Cell Biochemistry and Biophysics, 70, 1145- 1151. http://dx.doi.org/10.1007/s12013-014-0034-1
[33] Rakovitch, E., Nofech-Mozes, S., Hanna, W., Narod, S., Thiruchelvam, D., Saskin, R., Spayne, J., Taylor, C. and Paszat, L. (2012) HER2/Neu and Ki-67 Expression Predict Non-Invasive Recurrence Following Breast-Conserving Therapy for Ductal Carcinoma in Situ. British Journal of Cancer, 106, 1160-1165. http://dx.doi.org/10.1038/bjc.2012.41
[34] Nguyen, L.H., Black, M.J., Hier, M., Chauvin, P. and Rochon, L. (2003) HER2/Neu and Ki-67 as Prognostic Indicators in Mucoepidermoid Carcinoma of Salivary Glands. The Journal of Otolar-yngology, 32, 328-331.http://dx.doi.org/10.2310/7070.2003.11438
[35] Lukashina, M.I., Glukhova, E.I., Zhukova, L.G., Ermilova, V.D., Bogatyrev, V.N. and Baryshnikov, A.I. (2003) Her-2/Neu, Ki-67 Expression and Ploidy in Breast Carcinoma. Archives of Pathology, 65, 25-29.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.